Other

Operating Lease Income - 2023 (Lessor)

Neurocrine Biosciences Operating Lease Income - 2023 (Lessor) increased by 2.9% to $3.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.9%, from $3.50M to $3.60M. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionOther
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ3 2023
Last reportedQ1 2026May 5, 2026

How to read this metric

Higher values indicate a robust and stable pipeline of recurring revenue from the leasing segment.

Detailed definition

This metric forecasts the rental income expected to be generated from operating leases in a future fiscal year. Unlike f...

Peer comparison

Commonly reported in the maturity and future income disclosures of banks with significant operating lease portfolios.

Metric ID: operating_lease_income_2023_lessor

Historical Data

8 periods
 Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value$1.70M$1.70M$2.70M$3.50M$3.50M$3.50M$3.50M$3.60M
QoQ Change+0.0%+58.8%+29.6%+0.0%+0.0%+0.0%+2.9%
YoY Change+105.9%+105.9%+29.6%+0.0%+2.9%
Range$1.70M$3.60M
CAGR+53.5%
Avg YoY Growth+48.9%
Median YoY Growth+29.6%
Current Streak7+ quarters growth

Frequently Asked Questions

What is Neurocrine Biosciences's operating lease income - 2023 (lessor)?
Neurocrine Biosciences (NBIX) reported operating lease income - 2023 (lessor) of $3.60M in Q1 2026.
How has Neurocrine Biosciences's operating lease income - 2023 (lessor) changed year-over-year?
Neurocrine Biosciences's operating lease income - 2023 (lessor) increased by 2.9% year-over-year, from $3.50M to $3.60M.
What does operating lease income - 2023 (lessor) mean?
The projected rental income the bank expects to earn from operating leases in the specified future year.